<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492543</url>
  </required_header>
  <id_info>
    <org_study_id>CH-BC-014</org_study_id>
    <nct_id>NCT01492543</nct_id>
  </id_info>
  <brief_title>Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer</brief_title>
  <official_title>An Open-label, Single-arm, Multicenter, Phase II Study to Assess the Efficacy and Safety of Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule) as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness and safety profile of Aiyi®(Tegafur
      Gimeracil Oteracil Potassium Capsule, TS-1) as a second line therapy in Chinese female
      patients with advanced metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tegafur Gimeracil Oteracil Potassium Capsule is a novel oral derivative of the
      5-fluorouracil(5-FU) prodrug tegafur combined with two modulators. Recent clinical trial has
      reported the promising effect of Tegafur Gimeracil Oteracil Potassium Capsule in metastatic
      breast cancer. The innovative drug, S-1, has obtained the approval of treatment of advanced
      breast cancer in Japan, meanwhile, Generic drug is only approved for the indication of
      gastric cancer in China mainland by Chinese authority, SFDA, and no Chinese clinical study
      data of TS-1 in breast cancer so far.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate</measure>
    <time_frame>Every six weeks</time_frame>
    <description>Assessed by RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Subjects will be followed from date of enrollment until the date of last visit, anticipated up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Aiyi®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegafur Gimeracil Oteracil Potassium Capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur Gimeracil Oteracil Potassium Capsule</intervention_name>
    <description>Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,</description>
    <arm_group_label>Aiyi®</arm_group_label>
    <other_name>TS-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-75 years old female.

          -  ECOG status: 0-2.

          -  Life expectancy of ≥ 3 months.

          -  Histologic or cytologic diagnosis of breast cancer.

          -  Progression after receiving one standard prior chemotherapy regimen for recurrent or
             metastatic lesion except an endocrine regimen.

          -  At least one measurable lesion of &gt;=2 cm (&gt;=1 cm on spiral CT scan)according to RECIST
             (v1.1).

          -  Adequate organ functions:

               -  Hematopoietic: Hemoglobin ≥90g/L, Absolute neutrophil count ≥1.5×10^9/L, Platelet
                  count ≥80×10^9/L.

               -  Biochemistry: TBil ≤1.5 times upper limit of normal (ULN), AST and ALT ≤2.5×
                  ULN(≤5x ULN if due to liver metastases), Creatinine ≤1.0×ULN and Creatinine
                  clearance &gt;50 ml/min.

          -  Women with children potential must have negative pregnancy tests 7 days prior to
             enrollment and be willing to practice acceptable methods of birth control during the
             study and 8 weeks after last drug administered.

          -  Ability to take oral medication .

          -  Signed informed consent.

        Exclusion Criteria:

          -  Pregnancy or lactation or no effective contraception in fertile patients.

          -  Prior treatment with 5-FU or drugs of same class(excluding patients that relapsed more
             than one year after adjuvant therapy).

          -  Less than 4 weeks since prior investigational agents.

          -  conditions impacting oral drug taking or absorption (e.g. inability to swallow,
             gastrointestinal resection, chronic diarrhea, intestinal obstruction).

          -  Organ invasion with rapid progression(e.g. lesions exceeding half of Liver or Lung).

          -  CNS or psychiatric disorders.

          -  Allergic to 5-FU.

          -  Only with bone metastases and no measurable lesions.

          -  Clinically significant heart diseases (e.g.congestive heart failure, ventricular
             arrhythmia, myocardial infarction) before enrollment.

          -  Serious peptic ulcer disease or digestive disorders.

          -  Bone marrow (Hemoglobin &lt;90g/dl, ANC &lt;1.5×10^9/L, Platelet count &lt;75×10^9/L).

          -  Renal function disorder (Creatinine &gt;1.0×ULN).

          -  Liver function disorder (TBil &gt;1.5×ULN).

          -  Uncontrolled brain metastases.

          -  Noncompliance with the study protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binghe Xu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Yuan, MD</last_name>
    <phone>86-10-8778-8114</phone>
    <email>yuanpeng01@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Chao-yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Yu, MD</last_name>
      <phone>+86-13810292522</phone>
      <email>xiaoyugw@126.com</email>
    </contact>
    <investigator>
      <last_name>Hong Dai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dan Yu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donggui Wan, MD</last_name>
      <phone>+86-13601365686</phone>
      <email>dongguiwan@263.net</email>
    </contact>
    <investigator>
      <last_name>Donggui Wan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijun Di, MD</last_name>
      <phone>+86-8819-6406</phone>
      <email>Dilijun2012@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lijun Di, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huihui Rao, MD</last_name>
      <phone>+86-15110047147</phone>
      <email>15110047147@163.com</email>
    </contact>
    <investigator>
      <last_name>Junlan Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huihui Rao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei Provincial Tumor Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050019</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Long Wang, MD</last_name>
      <phone>+86-13803343508</phone>
      <email>125662333@qq.com</email>
    </contact>
    <investigator>
      <last_name>Wei Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Long Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongsheng Tong, MD</last_name>
      <phone>+86-13920458207</phone>
      <email>tonghang@medmail.com</email>
    </contact>
    <investigator>
      <last_name>Zhongsheng Tong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Yuan, MD</last_name>
      <phone>86-10-8778-8114</phone>
      <email>yuanpeng01@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Binghe Xu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peng Yuan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2011</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Binghe Xu</investigator_full_name>
    <investigator_title>Deputy Director of Department of Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Advanced</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

